{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:22:51Z","timestamp":1791595371088,"version":"4.3.4"},"reference-count":34,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,11]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>We investigated B-cell maturation antigen-directed chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) involvement. Ten patients received either idecabtagene vicleucel (n\u00a0=\u00a06) or ciltacabtagene autoleucel (n = 4), where brain\/cranial nerve and\/or spinal cord involvement\/leptomeningeal disease were evident on either magnetic resonance imaging (100%) and\/or cerebrospinal fluid (40%). Eight patients had their CNS diagnosis before CAR-T therapy, and two were diagnosed within 14 days post-infusion. Seven received CNS-directed therapy during bridging before CAR-T therapy. There were no excess toxicities: no cytokine release syndrome grade \u22653; 10% immune effector cell-associated neurotoxicity syndrome (ICANS) grade 3; and no ICANS grade 4. Two patients experienced delayed but treatable neurotoxicity, with no reported parkinsonian side effects. The best overall response rate was 80% (\u226570% very good partial response) and a 100% CNS response. With a median follow-up of 381 days, patients with CNS myeloma diagnosed before CAR-T therapy (n = 8) had a median overall survival and progression-free survival (PFS) of 13.3 and 6.3\u00a0months, respectively. Best outcomes were observed in 4 patients who had a response to bridging therapy, suggesting that optimizing pre-CAR-T therapy may be key for improved outcomes. Our study suggests that CAR-T therapy in patients with CNS MM is safe and feasible, and screening for CNS involvement before CAR-T therapy could be warranted in high-risk patients. The excellent initial response but relatively short PFS suggests consideration for post-CAR-T maintenance. Larger studies are needed to confirm these findings.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014345","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T18:16:26Z","timestamp":1735323386000},"page":"1171-1180","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3928-6590","authenticated-orcid":false,"given":"Mahmoud R.","family":"Gaballa","sequence":"first","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Castaneda","family":"Puglianini","sequence":"additional","affiliation":[{"name":"2Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-3843","authenticated-orcid":false,"given":"Adam","family":"Cohen","sequence":"additional","affiliation":[{"name":"3Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-2566","authenticated-orcid":false,"given":"Dan","family":"Vogl","sequence":"additional","affiliation":[{"name":"3Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0196-5456","authenticated-orcid":false,"given":"Alfred","family":"Chung","sequence":"additional","affiliation":[{"name":"4Division of Hematology\/Oncology, University of CA San Francisco Cancer Center, University of California, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Ferreri","sequence":"additional","affiliation":[{"name":"5Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Levine Cancer Institute, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1661-718X","authenticated-orcid":false,"given":"Peter","family":"Voorhees","sequence":"additional","affiliation":[{"name":"5Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Levine Cancer Institute, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"2Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"2025032513472641700_bib1","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"2025032513472641700_bib2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"issue":"1","key":"2025032513472641700_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2025032513472641700_bib4","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2025032513472641700_bib5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10297","key":"2025032513472641700_bib6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2025032513472641700_bib7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A\u00a0phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"issue":"14","key":"2025032513472641700_bib8","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood.2023021860","article-title":"BCMA-CAR T-cell treatment\u2013associated parkinsonism","volume":"142","author":"Gust","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032513472641700_bib9","doi-asserted-by":"crossref","first-page":"6937","DOI":"10.1182\/blood-2023-188090","article-title":"Incidence of parkinsonism as a complication of anti-BCMA CAR-T cell therapy in multiple myeloma","volume":"142","author":"Singh","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2025032513472641700_bib10","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2025032513472641700_bib11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","article-title":"Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients","volume":"7","author":"Cook","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"2025032513472641700_bib12","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1182\/blood.2021012932","article-title":"CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network","volume":"139","author":"Alcantara","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2025032513472641700_bib13","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.3324\/haematol.2023.282875","article-title":"CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes","volume":"108","author":"Lacan","year":"2023","journal-title":"Haematologica"},{"issue":"20","key":"2025032513472641700_bib14","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/bloodadvances.2020004106","article-title":"CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma","volume":"5","author":"Siddiqi","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"2025032513472641700_bib15","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"2025032513472641700_bib16","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.bbmt.2017.03.009","article-title":"Response assessment in myeloma: practical manual on consistent reporting in an era of dramatic therapeutic advances","volume":"23","author":"Garderet","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"2025032513472641700_bib17","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","article-title":"Pembrolizumab treatment for progressive multifocal leukoencephalopathy","volume":"380","author":"Cortese","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2025032513472641700_bib18","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2025032513472641700_bib19","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1182\/blood-2023-181762","article-title":"Real world outcomes with idecabtagene vicleucel (ide-cel) CAR-T cell therapy for relapsed\/refractory multiple myeloma","volume":"142","author":"Sidana","year":"2023","journal-title":"Blood"},{"issue":"suppl 16","key":"2025032513472641700_bib20","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1200\/JCO.2022.40.16_suppl.8042","article-title":"Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): real-world experience","volume":"40","author":"Hansen","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 16","key":"2025032513472641700_bib21","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1200\/JCO.2023.41.16_suppl.8012","article-title":"Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (cilta-cel) for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Hansen","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"2025032513472641700_bib22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-3-030-94353-0_34","volume-title":"The EBMT\/EHA CAR-T Cell Handbook","author":"Rodr\u00edguez-Otero","year":"2022"},{"key":"2025032513472641700_bib23","doi-asserted-by":"crossref","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"2025032513472641700_bib24","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.jtct.2023.12.051","article-title":"Immune engager therapies are associated with better outcomes in post ide-cel relapse in MM- an analysis of the US MM Immunotherapy Consortium Database","volume":"30","author":"Janakiram","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2025032513472641700_bib25","unstructured":"Minimal residual disease guided maintenance therapy with belantamab mafodotin and lenalidomide after autologous hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma. ClinicalTrials.gov identifier: NCT05091372. Updated 20 November 2024. Accessed 15 September 2024. https:\/\/clinicaltrials.gov\/study\/NCT05091372."},{"key":"2025032513472641700_bib26","unstructured":"Phase 2 study of belantamab mafodotin as pre- and post-autologous stem cell transplant consolidation and maintenance for multiple myeloma. ClinicalTrials.gov identifier: NCT04680468. Updated 23 October 2024. Accessed 15 September 2024. https:\/\/clinicaltrials.gov\/study\/NCT04680468."},{"key":"2025032513472641700_bib27","unstructured":"Belantamab mafadotin maintenance therapy after salvage autologous hematopoietic cell transplantation in patients with relapse refractory multiple myeloma. ClinicalTrials.gov identifier: NCT05065047. Updated 8 May 2024. Accessed 15 September 2024. https:\/\/clinicaltrials.gov\/study\/NCT05065047."},{"key":"2025032513472641700_bib28","unstructured":"Phase 2 trial of belantamab mafodotin consolidation treatment in patients with multiple myeloma and MRD positivity after autologous stem cell transplantation. ClinicalTrials.gov identifier: NCT04876248. Updated 1 November 2024. Accessed 15 September 2024. https:\/\/clinicaltrials.gov\/study\/NCT04876248."},{"key":"2025032513472641700_bib29","unstructured":"Phase 3 study of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone in participants with newly diagnosed multiple myeloma as maintenance therapy following autologous stem cell transplantation - MajesTEC-4. ClinicalTrials.gov identifier: NCT05243797. Updated 20 November 2024. Accessed 15 September 2024. https:\/\/clinicaltrials.gov\/study\/NCT05243797."},{"key":"2025032513472641700_bib30","unstructured":"MRD-guided sequential therapy for deep response in newly diagnosed multiple myeloma - MASTER-2 trial. ClinicalTrials.gov identifier: NCT05231629. Updated 16 December 2024. Accessed 15 September 2024. https:\/\/clinicaltrials.gov\/study\/NCT05231629."},{"key":"2025032513472641700_bib31","unstructured":"A multicenter phase II study of maintenance belantamab mafodotin (Blenrep\u00ae) after BCMA-directed chimeric antigen receptor T-cell therapy in patients with relapsed and\/or refractory multiple myeloma. ClinicalTrials.gov identifier: NCT05117008. Updated 9 August 2024. Accessed 15 September 2024. https:\/\/clinicaltrials.gov\/study\/NCT05117008."},{"issue":"7","key":"2025032513472641700_bib32","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3324\/haematol.2020.248518","article-title":"Multiple myeloma with central nervous system relapse","volume":"105","author":"Egan","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"2025032513472641700_bib33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"12","key":"2025032513472641700_bib34","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/5\/1171\/2357741\/blooda_adv-2024-014345-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/5\/1171\/2357741\/blooda_adv-2024-014345-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T23:40:39Z","timestamp":1742946039000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/5\/1171\/534846\/BCMA-directed-CAR-T-cell-therapy-in-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,3,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014345","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]}}}